Cointime

A-Mansia Biotech

company

About

A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium.

  • 1 - 10

Highlights

Total Funding Amount
€16M
Funding Rounds
2
Investors
4

Details

Last Funding Type
Series A
Last Funding Money Raised
€13M
Industries
Biopharma,Biotechnology,Life Science
Founded date
Jan 1, 2016
Number Of Employee
1 - 10
Operating Status
Active

A-Mansia Biotech is a developer of products based on the properties of the Akkermansia muciniphila (A. muciniphila) bacterium. The company's nutritional supplement based on a gut bacterium called Akkermansia, the population of microorganisms housed in the gastrointestinal tract. A. muciniphila is located in the mucus layer covering the intestinal epithelium, which allows the bacterium to establish a close cross-talk with the host.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
2
€16M
A-Mansia Biotech has raised a total of €16M in funding over 2 rounds. Their latest funding was raised on Apr 27, 2018 from a Series A round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Apr 27, 2018 Series A €13M 3 — — Detail
Apr 1, 2018 Grant €3M 1 Wallonia Regional Government — Detail

Investors

Number of Lead Investors
Number of Investors
1
4
A-Mansia Biotech is funded by 4 investors. Wallonia Regional Government and Fonds Vives II (University of Louvain, UCL) are the most recent investors.
Investor Name Lead Investor Funding Round
Wallonia Regional Government Yes Grant
Fonds Vives II (University of Louvain, UCL) — Series A
the SRIW Life Sciences — Series A
Nivelinvest — Series A
Cointime
İçerikler
Şirket.